医学
内科学
入射(几何)
丁型肝炎
丁型肝炎病毒
胃肠病学
病毒学
相(物质)
乙型肝炎表面抗原
肝炎
核糖核酸
临床试验
临床研究阶段
免疫学
丙型肝炎
作者
Tarik Asselah,Michael A. Chattergoon,Alina Jucov,Anca Streinu‐Cercel,Pietro Lampertico,Heiner H. Wedemeyer,Patrick T.F. Kennedy,Edward John Gane,Brianna L. Bullard,Sophia Chow,Desiree Santos,Grégory Camus,Yimeng Lu,Cara Pilowa,Carey K. Hwang,Todd A. Correll,Kosh Agarwal
标识
DOI:10.1056/nejmoa2508827
摘要
BACKGROUND: Both tobevibart (a monoclonal antibody) and elebsiran (a small interfering RNA) target hepatitis B virus surface antigen (HBsAg). Their efficacy and safety in the treatment of chronic hepatitis D virus (HDV) infection are unknown. METHODS: IU per milliliter from baseline (virologic response) and normalization of the alanine aminotransferase (ALT) level, at week 24. RESULTS: At week 24, a combined response was observed in 47% of participants (15 of 32) who received tobevibart plus elebsiran and in 70% of participants (23 of 33) who received tobevibart, with a virologic response in 100% (32 of 32) and 82% (27 of 33), respectively, and normalization of the ALT level in 47% (15 of 32) and 76% (25 of 33). At week 48, a combined response was observed in 56% of participants (18 of 32) with tobevibart plus elebsiran and 61% of participants (20 of 33) with tobevibart; undetectable HDV RNA (also known as target not detected, or TND; no amplification during reverse-transcriptase-polymerase-chain-reaction assay) in 66% (21 of 32) and 48% (16 of 33), respectively; normalization of the ALT level in 56% (18 of 32) and 61% (20 of 33); and an HBsAg level below 10 IU per milliliter in 91% (29 of 32) and 21% (7 of 33). No ALT flares were observed in participants starting tobevibart and elebsiran simultaneously or receiving tobevibart monotherapy. Through week 48, a total of 81% of participants who received tobevibart plus elebsiran and 94% of those who received tobevibart had at least one adverse event, primarily influenza-like illness and chills. CONCLUSIONS: In this phase 2 trial, tobevibart plus elebsiran as well as tobevibart monotherapy decreased HDV RNA and ALT levels through week 48. Treatment with tobevibart plus elebsiran was associated with a high incidence of undetectable HDV RNA and of a decrease in the HBsAg level. (Funded by Vir Biotechnology; ClinicalTrials.gov number, NCT05461170.).
科研通智能强力驱动
Strongly Powered by AbleSci AI